FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
FILANA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$0.68−0.02 (-3.06%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
26.2%
13M of 48M shares
Institutional holders
85
8 new, 22 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $718.95K
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FLNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,974,981 | 4.09% | $2.35M | +44,038 | 0.00% |
| Two Sigma Investments, LP | 1,711,358 | 3.54% | $2.04M | −277,456 | 0.00% |
| Marshall Wace, Llp | 1,597,548 | 3.31% | $1.90M | −414,995 | 0.00% |
| BlackRock, Inc. | 1,453,561 | 3.01% | $1.73M | +39,047 | 0.00% |
| Goldman Sachs Group Inc | 668,792 | 1.38% | $795.86K | +627,468 | 0.00% |
| Geode Capital Management, LLC | 615,510 | 1.27% | $732.74K | +19,268 | 0.00% |
| D. E. Shaw & Co., Inc. | 485,025 | 1.00% | $577.18K | −74,180 | 0.00% |
| Gmt Capital Corp | 450,100 | 0.93% | $535.62K | – | 0.03% |
| Renaissance Technologies LLC | 389,601 | 0.81% | $463.63K | +62,842 | 0.00% |
| Squarepoint Ops LLC | 318,380 | 0.66% | $378.87K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 315,889 | 0.65% | $375.91K | +41,958 | 0.00% |
| Acadian Asset Management LLC | 295,059 | 0.61% | $350 | +10,846 | 0.00% |
| Susquehanna International Group, Llp | 292,017 | 0.60% | $347.50K | −155,261 | 0.00% |
| Gsa Capital Partners Llp | 269,410 | 0.56% | $321 | +51,566 | 0.02% |
| Group One Trading, L.P. | 244,008 | 0.51% | $290.37K | −58,616 | 0.00% |
| State Street Corp | 209,105 | 0.43% | $248.84K | −30,882 | 0.00% |
| Vanguard Portfolio Management LLC | 132,597 | 0.27% | $157.79K | −96 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 132,298 | 0.27% | $157.44K | −4,633 | 0.00% |
| Federated Hermes, Inc. | 119,952 | 0.25% | $142.74K | +4,855 | 0.00% |
| Northern Trust Corp | 114,322 | 0.24% | $136.04K | −34,872 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 85 | 13M | 26.2% | 8 / 21 | 33 / 22 | 1M | 2M |
| Q1 2026 | 101 | 14M | 28.3% | 15 / 17 | 38 / 20 | 5M | 3M |
| Q4 2025 | 107 | 14M | 28.6% | 22 / 25 | 29 / 15 | 3M | 3M |
| Q3 2025 | 103 | 14M | 29.7% | 20 / 21 | 32 / 13 | 4M | 2M |
| Q2 2025 | 97 | 12M | 25.5% | 18 / 23 | 33 / 38 | 2M | 6M |
| Q1 2025 | 117 | 16M | 32.8% | 18 / 29 | 41 / 36 | 2M | 4M |
| Q4 2024 | 137 | 17M | 36.0% | 31 / 45 | 35 / 54 | 6M | 3M |
| Q3 2024 | 161 | 14M | 29.1% | 37 / 50 | 35 / 18 | 5M | 2M |
| Q2 2024 | 145 | 13M | 27.7% | 23 / 60 | 23 / 17 | 2M | 1M |
| Q1 2024 | 142 | 12M | 25.0% | 15 / 46 | 43 / 25 | 0M | 3M |
| Q4 2023 | 153 | 15M | 30.1% | 31 / 45 | 39 / 16 | 3M | 2M |
| Q3 2023 | 140 | 13M | 26.8% | 16 / 54 | 32 / 25 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FLNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,365,843 | 2.83% | $1.63M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 563,883 | 1.17% | $671.02K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 283,013 | 0.59% | $435.84K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 148,590 | 0.31% | $176.82K | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 132,117 | 0.27% | $203.46K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 81,461 | 0.17% | $125.45K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,474 | 0.15% | $111.61K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 42,605 | 0.09% | $50.70K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 39,953 | 0.08% | $61.53K | 0.00% | May 31, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 33,701 | 0.07% | $51.90K | 0.27% | May 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 31,056 | 0.06% | $31.37K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 24,525 | 0.05% | $29.18K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 20,730 | 0.04% | $24.67K | 0.00% | Jun 30, 2026 |
| Fidelity ZERO Extended Market Index Fund | 16,078 | 0.03% | $16.24K | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10,600 | 0.02% | $12.61K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard Barry | President & CEO, Director | 1,031,151 | 2.13% | Sep 30, 2026 |
| Robert Christopher Cook | Chief Operating & Legal Office | 13,725 | 0.03% | Oct 2, 2025 |
| Eric Schoen | Chief Financial Officer | 11,500 | 0.02% | Apr 21, 2025 |
| Freda Nassif | Chief Business Officer | – | – | Apr 21, 2025 |
| James William Kupiec | Chief Medical Officer | 0 | – | Dec 3, 2024 |
| Jaren Landen | Chief Clinical Dev. Officer | – | – | Nov 20, 2024 |
| Robert Eugene Anderson Jr | Director | 8,600 | 0.02% | Nov 25, 2025 |
| Dawn Carter Bir | Director | – | – | Oct 22, 2025 |
| Patrick J. Md Scannon Phd | Director | 1,000 | 0.00% | Jul 16, 2025 |
| Donnell Michael J. O | Director | 65,812 | 0.14% | May 27, 2025 |
| Pierre Gravier | Director | – | – | May 27, 2025 |
| Claude Nicaise | Director | – | – | May 27, 2025 |
| Robert Z. Gussin | Director | 10,617 | 0.02% | May 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Barry President & CEO, Director | Sep 28, 2026 | Buy | +93,091 | $0.84 | $78.20K | 1,031,151 |
| Robert Eugene Anderson Jr Director | Nov 24, 2025 | Buy | +8,600 | $2.90 | $24.94K | 8,600 |
| Richard Barry President & CEO, Director | Nov 20, 2025 | Buy | +150,000 | $2.76 | $414.00K | 938,060 |
| Richard Barry President & CEO, Director | Nov 19, 2025 | Buy | +73,385 | $2.75 | $201.81K | 788,060 |
| Robert Christopher Cook Chief Operating & Legal Office | Sep 30, 2025 | Buy | +13,725 | $2.91 | $39.94K | 13,725 |
| Richard Barry President & CEO, Director | Sep 22, 2025 | Buy | +7,172 | $2.28 | $16.35K | 714,675 |
| Richard Barry President & CEO, Director | Sep 19, 2025 | Buy | +46,908 | $2.29 | $107.42K | 707,503 |
| Richard Barry President & CEO, Director | Sep 19, 2025 | Buy | +400 | $2.25 | $900 | 660,595 |
| Richard Barry President & CEO, Director | Sep 18, 2025 | Buy | +185,233 | $2.24 | $414.92K | 660,195 |
| Richard Barry President & CEO, Director | Sep 18, 2025 | Buy | +5,400 | $2.13 | $11.50K | 474,962 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Sale | −59,800 | $3.86 | $230.83K | 11,500 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Sale | −2,000 | $3.82 | $7.64K | 0 |
| Eric Schoen Chief Financial Officer | Nov 29, 2024 | Option exercise | +50,000 | $1.18 | $59.00K | 71,300 |
| James William Kupiec Chief Medical Officer | Nov 29, 2024 | Sale | −4,000 | $3.87 | $15.48K | 0 |
| Sanford Robertson Director | May 16, 2024 | Gift | −5,000 | – | – | 950,851 |
| Sanford Robertson Director | May 16, 2024 | Gift | +5,000 | – | – | 5,000 |
| Sanford Robertson Director | Apr 26, 2024 | Option exercise | +69,000 | $22.00 | $1.52M | 955,851 |
| Richard Barry Director | Apr 23, 2024 | Option exercise | +176,085 | $22.00 | $3.87M | 469,562 |
| James William Kupiec Chief Medical Officer | Apr 18, 2024 | Option exercise | +1,500 | $22.00 | $33.00K | 4,000 |
| Eric Schoen Chief Financial Officer | Apr 17, 2024 | Option exercise | +1,500 | $22.00 | $33.00K | 21,300 |
| Sanford Robertson Director | Aug 23, 2023 | Buy | +30,000 | $17.45 | $523.50K | 886,851 |
| Richard Barry Director | Aug 22, 2023 | Buy | +16,571 | $16.65 | $275.91K | 293,477 |
| Richard Barry Director | Aug 21, 2023 | Buy | +1,906 | $16.80 | $32.02K | 276,906 |
| Patrick J. Md Scannon Phd Director | Jun 12, 2023 | Option exercise | +1,000 | $0.95 | $950 | 1,000 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Option exercise | +14,285 | $16.87 | $240.99K | 390,397 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Tax withholding | −47,723 | $25.25 | $1.21M | 734,279 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Option exercise | +71,428 | $16.87 | $1.20M | 782,002 |
| Remi Barbier President and CEO, Director | May 24, 2023 | Tax withholding | −9,545 | $25.25 | $241.01K | 380,852 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +2,142 | $16.66 | $35.69K | 856,851 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 851,138 |
| Sanford Robertson Director | May 10, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 854,709 |
| Robert Z. Gussin Director | May 1, 2023 | Tax withholding | +7,077 | $23.34 | $165.18K | 10,617 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +2,142 | $16.66 | $35.69K | 10,552 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 14,123 |
| Robert Z. Gussin Director | May 1, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 17,694 |
| Donnell Michael J. O Director | Mar 7, 2023 | Tax withholding | −2,778 | $25.20 | $70.01K | 6,873 |
| Donnell Michael J. O Director | Mar 7, 2023 | Tax withholding | −2,361 | $25.20 | $59.50K | 9,651 |
| Donnell Michael J. O Director | Mar 7, 2023 | Option exercise | +3,571 | $19.60 | $69.99K | 12,012 |
| Donnell Michael J. O Director | Mar 7, 2023 | Option exercise | +3,571 | $16.66 | $59.49K | 8,441 |
| Richard Barry Director | Mar 7, 2023 | Buy | +77,276 | $25.76 | $1.99M | 275,000 |
| Richard Barry Director | Mar 6, 2023 | Buy | +11,565 | $26.13 | $302.19K | 197,724 |
| Nadav Friedmann Chief Medical Officer, Director | Oct 3, 2022 | Option exercise | +9,376 | $0.95 | $8.91K | 79,910 |
| Sanford Robertson Director | Sep 8, 2022 | Option exercise | +2,802 | $23.59 | $66.10K | 1,027,567 |
| Richard Barry Director | Aug 23, 2022 | Buy | +36,159 | $23.79 | $860.22K | 186,159 |
| James William Kupiec Chief Clinical Dev. Officer | Aug 23, 2022 | Buy | +2,500 | $24.44 | $61.10K | 2,500 |
| Eric Schoen Chief Financial Officer | Aug 12, 2022 | Buy | +2,500 | $19.95 | $49.88K | 19,800 |
| Sanford Robertson Director | Aug 12, 2022 | Buy | +100,000 | $20.69 | $2.07M | 1,024,765 |
| Remi Barbier President and CEO, Director | Jun 7, 2022 | Other | −57,143 | – | – | 710,574 |
| Remi Barbier President and CEO, Director | Jun 6, 2022 | Tax withholding | −54,720 | $27.93 | $1.53M | 767,717 |
| Remi Barbier President and CEO, Director | Jun 6, 2022 | Option exercise | +65,368 | $23.38 | $1.53M | 822,437 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Tax withholding | −21,498 | $26.66 | $573.14K | 70,534 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Option exercise | +3,501 | $23.38 | $81.85K | 70,590 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Option exercise | +24,513 | $23.38 | $573.11K | 95,103 |
| Nadav Friedmann Chief Medical Officer, Director | May 27, 2022 | Tax withholding | −3,071 | $26.66 | $81.87K | 92,032 |
| Remi Barbier President and CEO, Director | Apr 25, 2022 | Option exercise | +44,791 | $0.95 | $42.55K | 371,443 |
| Remi Barbier President and CEO, Director | Apr 25, 2022 | Option exercise | +4,669 | $16.31 | $76.15K | 376,112 |
| Robert Z. Gussin Director | Mar 29, 2022 | Option exercise | +2,801 | $23.59 | $66.08K | 12,434 |
| Robert Z. Gussin Director | Mar 29, 2022 | Option exercise | +4,669 | $20.30 | $94.78K | 9,633 |
| Robert Z. Gussin Director | Mar 29, 2022 | Tax withholding | −4,024 | $39.98 | $160.88K | 8,410 |
| Sanford Robertson Director | Mar 25, 2022 | Option exercise | +4,670 | $20.30 | $94.80K | 924,765 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Schoen, Eric J. (SAVA) Officer | Dec 2, 2024 | 2,000 | $7.64K | Nov 29, 2024 | RETAIL PURCHASE |
| Eric Schoen Officer | Nov 29, 2024 | 59,800 | $230.97K | Nov 29, 2024 | STOCK OPTION EXERCISE |